A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants (Z650)

A Single-center, Open, Self-controlled Design Clinical Study to Evaluate the Pharmacokinetic Effects of Rifampicin or Itraconazole on Single-dose Laolotinib Mesylate Capsules in Healthy Subjects

The purpose of this study is to characterize the effect of rifampin (Part A) and itraconazole(Part B) on the single-dose pharmacokinetics (PK) of Larotinib in healthy adult participants.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: Rifampin; Drug: Larotinib; Drug: Itraconazole

Detailed Description

The drug being tested in this study is called Larotinib (Z650). The study assessed the drug-drug interaction of Larotinib with either a strong cytochrome P-450 (CYP)3A inducer, rifampin (Part A) , or with a strong CYP3A inhibitor itraconazole (Part B) in healthy adult participants.

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Jilin
    • Changchun, Jilin, China, 130000
      • First Hospital of Jilin University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. The informed consent was signed before the study, and the content, process and possible adverse reactions of the study were fully understood;
2. Without Plan for pregnancy or pregnant within 6 months from screening to the last dose of the study drug;
3. Healthy, adult, male or female, 18 - 55 years of age;
4. Male subjects should weigh at least 50 kg and female subjects should weigh at least 45 kg. Body mass index (BMI) ≥18.0 and ≤28.0 kg/m2;
5. Subjects, who are healthy, as having no clinically significant abnormalities in vital signs and physical examination.

Exclusion Criteria:

1. Average daily smoking >5 cigarettes in 3 months before the study;
2. Known allergic reactions or hypersensitivity to any excipient of the study drug formulation(s).
3. History of alcoholism(defined as Alcohol consumption of > 14 units/week);
4. Those with positive urine drug screening or those with a history of drug abuse or drug use in the past five years ;
5. Blood donation or significant blood loss (>450 mL) within 3 months prior to screening;
6. Have dysphagia or have gastrointestinal, liver, or kidney disease (whether cured or not) that affects drug absorption or excretion within 6 months prior to screening;
7. Have any medical condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or stomach and duodenal ulcers ;
8. Use of any prescription drugs, over-the-counter drugs, any vitamin products or herbal medicines in the 14 days prior to screening;
9. Any drugs that changed the activity of liver drug enzymes, such as barbiturates and rifampicin, were taken within 30 days before screening;
10. Have taken the following inhibitors or inducers of CYP3A4, CYP2C8, CYP2C19 and P-GP within 30 days before screening;
11. Patients who had taken special diet (including pitaya, mango, grapefruit, etc.) or had strenuous exercise, or had other factors affecting drug absorption, distribution, metabolism and excretion, as judged by the researcher, within 14 days before screening ;
12. Participants who have participated in any drug clinical trials within 3 months prior to screening and have used the test drug (subjects may be enrolled in the study if they dropped out of the study prior to dosing, i.e., were not randomized or received dosing) ;
13. Abnormal abdominal ultrasonography, chest radiography, ECG examination is clinically significant, or the corrected QT interval (QTcF) of ECG >470ms during screening period ;
14. Female subjects were lactating or had positive blood pregnancy results at screening or check in;
15. Laboratory examination is abnormal and clinically significant, or the following diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, lung, immune, psychiatric or cardiovascular and cerebrovascular diseases) are clinically significant as found within 12 months prior to screening;
16. Viral hepatitis (including hepatitis B and C), HIV antigen/antibody or treponema pallidum antibody was positive at screening;
17. Acute illness or concomitant medication was occurred from the screening to the first administration of the experimental drug;
18. Subjects who consume chocolate, any food or drink containing caffeine or rich in xanthine within 24 hours before taking the study drug;
19. Alcohol breath test is positive at check-in.
20. Subjects who received vaccination within 28 days prior to screening or who plan to receive vaccination during the trial ;
21. The investigator deemed the subject unsuitable for this study for any reason

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part A, Treatment Sequence(Larotinib-Larotinib/Rifampin); Larotinib , capsules (150mg*2+50mg*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to 26, participants received rifampin 600 mg as capsules, orally, once daily (QD) and Larotinib 350 mg as capsules, orally was coadministered on Day 20. There was a washout period of 13 days between the two treatments.	Drug: Rifampin; Rifampin Capsules; Other Names: Rifampin Capsules; Drug: Larotinib; Larotinib Capsules; Other Names: Z650
Experimental: Part B, Treatment Sequence(Larotinib-Larotinib/itraconazole); Larotinib , capsules (150mg*2+50mg*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to Day 25, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 15 to Day 25 and a single oral dose of Larotinib 350 mg as capsule was coadministered on Day 19 (Treatment B). There was a washout period of 13 days between the two treatments.	Drug: Larotinib; Larotinib Capsules; Other Names: Z650; Drug: Itraconazole; Itraconazole Capsules; Other Names: Itraconazole Capsules

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	Maximum Observed Plasma Concentration of Larotinib	Day 1 pre-dose at multiple time points (up to 192 hours) post-dose
AUC∞	Area Under the Plasma Concentration-time Curve from Time 0 to Infinity, calculated using the observed value of the last quantifiable concentration for Larotinib	Day 1 pre-dose at multiple time points (up to 192 hours) post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUClast	Area Under the Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Larotinib	Day 1 pre-dose at multiple time points (up to 192 hours) post-dose
Tmax	Time to Reach the Maximum Plasma Concentration (Cmax) for Larotinib	Day 1 pre-dose at multiple time points (up to 192 hours) post-dose

Collaborators and Investigators

• Sponsor: Sunshine Lake Pharma Co., Ltd.
• Investigators: Principal Investigator: Yanhua Ding, The First Hospital of Jilin University

Study record dates

Study Major Dates

• Study Start (Actual): November 24, 2021
• Primary Completion (Actual): February 17, 2022
• Study Completion (Actual): September 28, 2023

Study Registration Dates

• First Submitted: August 31, 2021
• First Submitted That Met QC Criteria: September 16, 2021
• First Posted (Actual): September 27, 2021

Study Record Updates

• Last Update Posted (Actual): May 18, 2025
• Last Update Submitted That Met QC Criteria: May 16, 2025
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Hormones, Hormone Substitutes, and Hormone Antagonists; Enzyme Inhibitors; Nucleic Acid Synthesis Inhibitors; Steroid Synthesis Inhibitors; Hormone Antagonists; Cytochrome P-450 Enzyme Inhibitors; Antibiotics, Antitubercular; Antitubercular Agents; Cytochrome P-450 CYP3A Inhibitors; Leprostatic Agents; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP3A Inducers; 14-alpha Demethylase Inhibitors; Rifampin; Itraconazole; Hydroxyitraconazole
• Other Study ID Numbers: Z650-DDI-104

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No